Unlocking the Mystery of Hereditary Gelsolin Amyloidosis: A Korean Family's Genetic Journey
"Whole-exome sequencing (WES) reveals a rare p.D214Y mutation in the GSN gene, marking the first reported case of HGA in a Korean family and offering new hope for diagnosis and treatment."
Hereditary gelsolin amyloidosis (HGA), also known as familial amyloidosis of the Finnish type (FAF), is a rare, autosomal dominant amyloidosis. This means it's passed down through families and only one copy of the mutated gene is needed to cause the condition. HGA is characterized by a trio of distinctive symptoms: corneal lattice dystrophy (an eye disorder), peripheral neuropathy (nerve damage affecting the limbs), and cutis laxa (loose, sagging skin).
While HGA has been identified in various ethnic groups worldwide, including Finnish, Japanese, and Danish families, it had never been reported in Korean patients until now. The typical onset of HGA occurs in the third or fourth decade of life, initially presenting with corneal lattice dystrophy. Over time, individuals develop cutis laxa and slowly progressive neuropathy, leading to a range of debilitating symptoms.
This article delves into the groundbreaking case of a Korean family diagnosed with HGA through advanced whole-exome sequencing (WES). We'll explore how the identification of a specific genetic mutation, p.D214Y in the gelsolin (GSN) gene, not only provided a definitive diagnosis for this family but also highlights the increasing role of WES in diagnosing rare and complex neuropathies.
Why Amyloidosis Statistics Vary
Amyloidosis statistics depend on which type is counted and whether totals include only confirmed diagnoses or also cases identified incidentally at autopsy or through screening studies, according to Biology Insights. The sources provided do not give a single prevalence figure for gelsolin amyloidosis or amyloidosis overall. Science Insights notes that wild-type and hereditary transthyretin amyloidosis were long considered extremely rare, but that this picture has changed. The Amyloidosis Foundation describes hereditary amyloidosis as disease caused by an inherited gene mutation that produces an abnormally shaped amyloid protein.
Testing and Diagnostic Considerations
Laboratory evaluation of hereditary amyloidoses can include Congo Red staining, immunoperoxidase staining of tissue, mass spectrometry, and genetic evaluation in familial cases. Genetic testing may involve emotional, social, or financial consequences; MedlinePlus also notes that physical risks are generally very small for tests using a blood sample or cheek-cell sample. The NIH Genetic Testing Registry provides information about hereditary amyloidosis, available tests, clinical features, and links to practice guidelines and other authoritative resources. These sources describe diagnostic tools and potential testing burdens, but do not establish one universal testing pathway for every patient.
Finnish Roots and a Founder Variant
Finnish gelsolin amyloidosis, also called AGel amyloidosis, is described in the 2026 preprint as an autosomal dominant systemic disease caused by the GSN c.640G>A p.D187N (rs121909715) founder variant. The disease was first described in 1969, and researchers hypothesized that Finnish patients shared a common ancestor dating to the 14th century. A 2017 report states that investigators identified 79 Finnish AGel families, comprising 707 patients, through patient interviews, genealogic studies, and civil and parish registers. The 2026 preprint also points to a link between regions with high incidence, Kanta-Häme and Kymenlaakso.
The Diagnostic Puzzle: Unraveling the Symptoms
The index patient, a 58-year-old Korean male, presented with a constellation of concerning symptoms, including involuntary facial twitching, progressive bilateral facial weakness, and tongue atrophy. These symptoms had been gradually worsening over four years, since the age of 54. Compounding the diagnostic challenge, his mother, maternal uncle, two sisters, and son exhibited similar symptoms, pointing towards a possible hereditary condition.
- Nerve conduction study (NCS): Revealed reduced compound muscle action potential (CMAP) amplitudes and conduction velocity in the left facial nerve.
- Electromyography (EMG): Showed reduced recruitment of motor unit action potential in specific muscles.
- Autonomic function tests (AFTs): Indicated sympathetic skin response abnormalities.
A Broader Clinical and Geographic Picture
A review describes hereditary gelsolin amyloidosis as first identified in Finland, which has the largest number of patients, while also noting reported cases in several other countries. A Korean study of clinical features and brain MRI findings notes that AGel amyloidosis had previously been observed in only two Korean patients and included age- and sex-matched healthy controls to address that limitation. Together, these reports show research extending beyond the Finnish setting, while the supplied excerpts do not provide detailed findings from the Korean study. The sources therefore support a growing international clinical literature, not a specific estimate of how common the disease is in Korea.
Diagnostic Oversight and Genetic Evidence
Hereditary gelsolin amyloidosis can be overlooked when clinicians consider amyotrophic lateral sclerosis or bulbar motor neuron disease, according to a report on a case that mimicked progressive bulbar symptoms. The source notes that the disease has not been listed as an MND mimic in some consensus guidelines and research articles, even though genetic testing is now widely available. In a report on the first Korean family with hereditary gelsolin amyloidosis caused by the GSN p.D214Y mutation, 20 variants were present in affected individuals but not in unaffected individuals. These examples illustrate both the risk of diagnostic omission and the use of genetic comparison within a family; they do not quantify how often either problem occurs.
The Power of WES: A New Era for Diagnosing Rare Diseases
This case marks the first reported instance of HGA in a Korean family and highlights the crucial role of WES in diagnosing rare and often misdiagnosed conditions. While traditional diagnostic approaches rely on recognizing specific clinical features, the phenotypic manifestations of HGA can vary, making diagnosis challenging.
Complex Cases Can Prompt Targeted Testing
A published case of mixed hereditary gelsolin amyloidosis and drug-induced myopathy describes complex muscle pathology that led clinicians to targeted genetic testing. Testing revealed an autosomal dominant pathogenic c.640G>A variant in the gelsolin gene. A separate review characterizes gelsolin amyloidosis as a condition whose genetics, biochemistry, and pathology have been examined, while the supplied excerpt does not detail particular therapeutic strategies. The case illustrates how an unusual clinical presentation can lead to a genetic finding, but it does not establish how commonly this diagnostic sequence occurs.
Earlier Detection and Better Options
An Amyloidosis Alliance overview highlights research developments in new treatment approaches and biomarkers that could support earlier detection. A 2025 review focused specifically on light-chain (AL) amyloidosis describes its diagnostic workflow as complex and resource-intensive and calls for novel approaches to expedite diagnosis and optimize the process. The Lancet’s 2026 review says amyloidosis had until recently been rapidly fatal with few therapeutic options, while noting that several new developments have emerged. These sources point to broader momentum in amyloidosis research, but do not specify a future treatment or diagnostic breakthrough for gelsolin amyloidosis.
Variation in Disease Expression
A report exploring clinical variability in gelsolin amyloidosis describes patients whose presentations underscore the disease’s diversity and suggest possible environmental influences on how it is expressed. The authors say genetic confirmation and confocal microscopy findings reaffirmed the genetic basis, while also raising questions about how best to assess systemic disease severity. They call for further investigation in larger cohorts. A separate 2025 report describes the first reported cardiac amyloidosis case involving both wild-type transthyretin and a novel gelsolin variant, p.Y474N; the article notes that previously reported dual amyloid cases most often involved ATTR and AL.
WES offers a powerful alternative, allowing clinicians to identify the underlying genetic cause, even in the absence of classic symptoms. In this case, WES not only confirmed the diagnosis of HGA but also facilitated genetic counseling for the family, enabling them to understand the inheritance pattern and assess the risk for future generations.
The successful diagnosis of HGA in this Korean family underscores the transformative potential of genomic medicine. As WES becomes more accessible and affordable, it is poised to play an increasingly important role in diagnosing and managing a wide range of rare and complex genetic disorders, offering hope for improved outcomes and personalized treatment strategies.